Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Abeona Therapeutics Inc (ABEO) Insider Trading Activity
Healthcare • Biotechnology • 84 employees
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Total Value
-$280,330.97
Total Shares
831,147
Average Trade Value
-$11,213.24
Most Active Insider
Alvino Mark
Total Activity: $136,764
Largest Single Transaction
$116,764
by Alvino Mark on Jun 18, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Executive Officer
Director, Officer
|
Oct 16, 2024 | 251 | $1,642 | 903,887 (-0.0%) | Payment of Exercise Price | |
|
Chief Executive Officer
Director, Officer
|
Sep 28, 2024 | 18,798 | $110,720 | 904,138 (-2.1%) | Payment of Exercise Price | |
|
Chief Financial Officer
Officer
|
Sep 28, 2024 | 6,388 | $37,625 | 365,217 (-1.7%) | Payment of Exercise Price | |
|
Svp, General Counsel
Officer
|
Sep 28, 2024 | 6,579 | $38,750 | 273,289 (-2.4%) | Payment of Exercise Price | |
|
Svp, General Counsel
Officer
|
Sep 20, 2024 | 496 | $2,986 | 279,868 (-0.2%) | Payment of Exercise Price | |
|
Director
|
Aug 26, 2024 | 11,797 | $10,000 | 114,511 (+10.3%) | Grant | |
|
Director
|
Aug 26, 2024 | 11,797 | $0 | 144,365 (+8.2%) | Grant | |
|
Director
|
Aug 26, 2024 | 11,797 | $10,000 | 72,334 (+16.3%) | Grant | |
|
Director
|
Aug 26, 2024 | 11,797 | $10,000 | 113,731 (+10.4%) | Grant | |
|
Director
|
Aug 26, 2024 | 11,797 | $0 | 97,471 (+12.1%) | Grant | |
|
Director
|
Aug 26, 2024 | 11,797 | $10,000 | 118,265 (+10.0%) | Grant | |
|
Director
|
Aug 13, 2024 | 11,044 | $10,000 | 11,044 (+100.0%) | Grant | |
|
Director
|
Aug 13, 2024 | 11,044 | $10,000 | 11,044 (+100.0%) | Grant | |
|
Chief Financial Officer
Officer
|
Jul 21, 2024 | 1,055 | $5,391 | 371,605 (-0.3%) | Payment of Exercise Price | |
|
Svp, General Counsel
Officer
|
Jul 8, 2024 | 102,689 | $10,000 | 280,364 (+36.6%) | Grant | |
|
Director
|
Jul 8, 2024 | 23,611 | $10,000 | 106,468 (+22.2%) | Grant | |
|
Chief Financial Officer
Officer
|
Jul 8, 2024 | 155,200 | $10,000 | 372,660 (+41.6%) | Grant | |
|
Director
|
Jul 8, 2024 | 23,611 | $10,000 | 60,537 (+39.0%) | Grant | |
|
Director
|
Jul 8, 2024 | 23,611 | $10,000 | 102,714 (+23.0%) | Grant | |
|
Chief Executive Officer
Director, Officer
|
Jul 8, 2024 | 424,000 | $10,000 | 922,936 (+45.9%) | Grant | |
|
Director
|
Jul 8, 2024 | 23,611 | $10,000 | 132,568 (+17.8%) | Grant | |
|
Director
|
Jul 8, 2024 | 23,611 | $10,000 | 85,674 (+27.6%) | Grant | |
|
Director
|
Jul 8, 2024 | 23,611 | $10,000 | 101,934 (+23.2%) | Grant | |
|
Director
|
Jun 18, 2024 | 25,821 | $116,453 | 62,063 (-41.6%) | Sale | |
|
Director
|
Jun 18, 2024 | 25,890 | $116,764 | 36,926 (-70.1%) | Sale |